fashion -WSS

fashion

author：entertainment 2025-09-30 17:04:09 - browse：83

The building exterior of AstraZeneca, a pharmaceutical and biopharmaceutical company, under cloudless blue sky — coverage from STAT — Adobe

WILMINGTON, Del. — Wednesday was the first time that a federal judge asked questions in-person of drug industry lawyers who are trying to stop Medicare from negotiating drug prices. It didn’t go well for them.

AstraZeneca’s lawyers argued that Medicare’s new powers amount to a taking of their property rights without due process. But Colm Connolly, chief judge of the U.S. District Court of Delaware, said he doesn’t understand how the law deprives AstraZeneca of its property. He asked Catherine Stetson, who represents AstraZeneca, multiple times to explain what property the company would lose due to Medicare price negotiation. Stetson said it’s both the patent and the drug that’s subject to the patent.

“You’re free to do what you want,” Connolly said, adding that drug companies don’t have to sell to Medicare. “You may not make as much money.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： First Opinion Podcast: Long Covid needs a new approach

WSS

Wearables generate powerful data but its not useful to doctors, yet

Pharmacists can make shortage drugs, but at what cost?

FDA gives detailed accounting of AI

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Pharmacists can make shortage drugs, but at what cost?

Pharmacists can make shortage drugs, but at what cost?

entertainment

fashion

explore

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

As demand for Covid shots wanes, Moderna seeks its next success

When prostate cancer spreads, where it goes matters

Medicare details structure of new drug price negotiation program

STAT Summit: GSK CEO on pharma giant's new direction

23andMe had bad news about my health. I wish a person had delivered it

STAT Summit: Michael J. Fox on progress in Parkinson's research

United colonoscopy coverage change 'may cost lives,' doctors say

Arc Institute generative AI designs new CRISPR systems

entertainment

FDA gives detailed accounting of AI

CEOs share strategies for surviving biotech slump

Readout LOUD podcast: Live from STAT Breakthrough Summit West

FDA gives detailed accounting of AI

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

Hospital price transparency does save money, advocate argues

knowledge

leisure time

explore

Wikipedia